GENAV18557 Dosing Poster

16"

24"

For Acute Ischemic Stroke

Activase® (alteplase) Dosing and Administration[1]

Dosing

The recommended dose of Activase is 0.9 mg/kg (not to exceed 90 mg total dose) infused intravenously over 60 minutes with 10% of the total dose administered as an initial bolus over 1 minute.

For information on reconstitution of 50- and 100-mg vials of Activase, see full Prescribing Information.

Administration

Step 1
INSPECT SOLUTION

After reconstitution to 1 mg/mL, inspect the solution for particulate matter and discoloration prior to administration.

The reconstituted preparation results in a colorless to pale yellow transparent solution.

Step 2
DISCARD EXCESS



To ensure proper dosing, discard excess by removing from the vial any quantity of drug in excess of that specified for the patient's treatment.

- Slightly tilt the vial and insert the needle into the **keyhole port** of the vial top, away from the puncture site made by the transfer device

Alternative option:

At this step, you can prepare the infusion set and remove excess from the injection port.

Step 3
PREPARE BOLUS



The bolus dose is 10% of the 0.9-mg/kg dose. Prepare it one of the following ways, using a syringe and needle:

1. Remove the dose from the Y-site injection port on the infusion line after the infusion set is primed;

OR

2. Remove the dose from the vial before the vial is attached to the infusion set. Be sure to insert the needle into the **keyhole port** of the vial top, away from the puncture site made by the transfer device.

Step 4
PREPARE INFUSION SET



100-mg vials

- Insert the spike end of an infusion set through the center of the stopper of the vial of reconstituted Activase, **using the same puncture site made by the transfer device**
- Peel the clear plastic hanger from the vial label. Hang the Activase vial from the resulting loop

50-mg vials

- Administer using either a polyvinyl chloride bag or glass vial and infusion set

Step 5
PRIME INFUSION SET

Prime infusion set tubing with Activase solution.

Step 6
ADMINISTER BOLUS

Administer initial IV bolus over 1 minute.

Administer IV bolus directly through the IV port or program the infusion pump to deliver the bolus dose.

Step 7
ADMINISTER REMAINDER

Immediately following the bolus dose, infuse the remaining 90% of the 0.9-mg/kg dose over 60 minutes.

Step 8
FLUSH IV TUBING

To ensure the full dose is delivered:

- Spike a small bag (eg, 50 mL) of 0.9% Sodium Chloride, USP, with end of the Activase infusion set when the Activase vial is empty. The infusion should continue at the same rate

No medication should be added to infusion solutions that contain Activase.
For additional information regarding dosing and administration, please see the Activase full Prescribing Information.

Indication

Activase is indicated for the treatment of acute ischemic stroke. Exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment. Initiate treatment as soon as possible but within 3 hours after symptom onset.

Important Select Safety Information

Contraindications

Do not administer Activase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit: current intracranial hemorrhage (ICH); subarachnoid hemorrhage; active internal bleeding; recent (within 3 months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding; bleeding diathesis; and current severe uncontrolled hypertension.

Warnings and Precautions

Bleeding

Activase can cause significant, sometimes fatal, internal or external bleeding, especially at arterial and venous puncture sites. Avoid intramuscular injections and trauma to the patient. Fatal cases of hemorrhage associated with traumatic intubation in patients administered Activase have been reported. Heparin, aspirin, or Activase may cause bleeding complications; therefore carefully monitor for bleeding. If serious bleeding occurs, terminate the Activase infusion.

Orolingual Angioedema

Monitor patients during and for several hours after infusion for orolingual angioedema. If angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy.

Cholesterol Embolization

Cholesterol embolism, sometimes fatal, has been reported rarely in patients treated with thrombolytic agents.

Coagulation Tests May be Unreliable during Activase Therapy

Coagulation tests and/or measures of fibrinolytic activity may be unreliable during Activase therapy.

Adverse Reactions

The most frequent adverse reaction associated with Activase AIS therapy is bleeding.

Allergic-type reactions, e.g., anaphylactoid reaction, laryngeal edema, orolingual angioedema, rash, and urticaria have been reported.

Please see the accompanying full Prescribing Information for additional Important Safety Information.

Genentech
A Member of the Roche Group

Printed in USA. ACI/121614004012(2)

ACTIVASE® ALTEPLASE

www.activase.com

Weight (lb)	Weight (kg)	Total Dose	Discard Quantity*	Bolus Dose (over 1 minute)	Infusion Dose (over 60 minutes)
90	40.9	36.8	63.2	3.7	33.1
92	41.8	37.6	62.4	3.8	33.8
94	42.7	38.4	61.6	3.8	34.6
96	43.6	39.2	60.8	3.9	35.3
98	44.5	40.1	59.9	4.0	36.1
100	45.5	41.0	59.0	4.1	36.9
102	46.4	41.8	58.2	4.2	37.6
104	47.3	42.6	57.4	4.3	38.3
106	48.2	43.4	56.6	4.3	39.1
108	49.1	44.2	55.8	4.4	39.8
110	50.0	45.0	55.0	4.5	40.5
112	50.9	45.8	54.2	4.6	41.2
114	51.8	46.6	53.4	4.7	41.9
116	52.7	47.4	52.6	4.7	42.7
118	53.6	48.2	51.8	4.8	43.4
120	54.6	49.1	50.9	4.9	44.2
122	55.5	50.0	50.0	5.0	45.0
124	56.4	50.8	49.2	5.1	45.7
126	57.3	51.6	48.4	5.2	46.4
128	58.2	52.4	47.6	5.2	47.2
130	59.1	53.2	46.8	5.3	47.9
132	60.0	54.0	46.0	5.4	48.6
134	60.9	54.8	45.2	5.5	49.3
136	61.8	55.6	44.4	5.6	50.0
138	62.7	56.4	43.6	5.6	50.8
140	63.6	57.2	42.8	5.7	51.5
142	64.5	58.1	41.9	5.8	52.3
144	65.5	59.0	41.0	5.9	53.1
146	66.4	59.8	40.2	6.0	53.8
148	67.3	60.6	39.4	6.1	54.5
150	68.2	61.4	38.6	6.1	55.3
152	69.1	62.2	37.8	6.2	56.0
154	70.0	63.0	37.0	6.3	56.7
156	70.9	63.8	36.2	6.4	57.4
158	71.8	64.6	35.4	6.5	58.1
160	72.7	65.4	34.6	6.5	58.9
162	73.6	66.2	33.8	6.6	59.6
164	74.5	67.1	32.9	6.7	60.4
166	75.5	68.0	32.0	6.8	61.2
168	76.4	68.8	31.2	6.9	61.9
170	77.3	69.6	30.4	7.0	62.6
172	78.2	70.4	29.6	7.0	63.4
174	79.1	71.2	28.8	7.1	64.1
176	80.0	72.0	28.0	7.2	64.8
178	80.9	72.8	27.2	7.3	65.5
180	81.8	73.6	26.4	7.4	66.2
182	82.7	74.4	25.6	7.4	67.0
184	83.6	75.2	24.8	7.5	67.7
186	84.5	76.1	23.9	7.6	68.5
188	85.5	77.0	23.0	7.7	69.3
190	86.4	77.8	22.2	7.8	70.0
192	87.3	78.6	21.4	7.9	70.7
194	88.2	79.4	20.6	7.9	71.5
196	89.1	80.2	19.8	8.0	72.2
198	90.0	81.0	19.0	8.1	72.9
200	90.9	81.8	18.2	8.2	73.6
202	91.8	82.6	17.4	8.3	74.3
204	92.7	83.4	16.6	8.3	75.1
206	93.6	84.2	15.8	8.4	75.8
208	94.5	85.1	14.9	8.5	76.6
210	95.5	86.0	14.0	8.6	77.4
212	96.4	86.8	13.2	8.7	78.1
214	97.3	87.6	12.4	8.8	78.8
216	98.2	88.4	11.6	8.8	79.6
218	99.1	89.2	10.8	8.9	80.3
≥220	≥100.0	90.0	10.0	9.0	81.0

*Calculations based on 100-mg vial of Activase.

Reference: 1. Activase [prescribing information]. South San Francisco, CA: Genentech, Inc; 2017.

For Acute Ischemic Stroke

Activase® (alteplase) Dosing and Administration[1]

Dosing

The recommended dose of Activase is 0.9 mg/kg (not to exceed 90 mg total dose) infused intravenously over 60 minutes with 10% of the total dose administered as an initial bolus over 1 minute.

For information on reconstitution of 50- and 100-mg vials of Activase, see full Prescribing Information.

Administration

Step 1
INSPECT SOLUTION

After reconstitution to 1 mg/mL, inspect the solution for particulate matter and discoloration prior to administration.

The reconstituted preparation results in a colorless to pale yellow transparent solution.

Step 2
DISCARD EXCESS



DO NOT prime syringe

To ensure proper dosing, discard excess by removing from the vial any quantity of drug in excess of that specified for the patient's treatment.

- Slightly tilt the vial and insert the needle into the **keyhole port** of the vial top, away from the puncture site made by the transfer device

Alternative option:

At this step, you can prepare the infusion set and remove excess from the injection port.

Step 3
PREPARE BOLUS



DO NOT prime syringe



The bolus dose is 10% of the 0.9-mg/kg dose. Prepare it one of the following ways, using a syringe and needle:

1. Remove the dose from the Y-site injection port on the infusion line after the infusion set is primed;

OR

2. Remove the dose from the vial before the vial is attached to the infusion set. Be sure to insert the needle into the **keyhole port** of the vial top, away from the puncture site made by the transfer device.

Step 4
PREPARE INFUSION SET





100-mg vials

- Insert the spike end of an infusion set through the center of the stopper of the vial of reconstituted Activase, **using the same puncture site made by the transfer device**
- Peel the clear plastic hanger from the vial label. Hang the Activase vial from the resulting loop

50-mg vials

- Administer using either a polyvinyl chloride bag or glass vial and infusion set

Step 5
PRIME INFUSION SET

Prime infusion set tubing with Activase solution.

Step 6
ADMINISTER BOLUS

Administer initial IV bolus over 1 minute.

Administer IV bolus directly through the IV port or program the infusion pump to deliver the bolus dose.

Step 7
ADMINISTER REMAINDER

Immediately following the bolus dose, infuse the remaining 90% of the 0.9-mg/kg dose over 60 minutes.

Step 8
FLUSH IV TUBING



To ensure the full dose is delivered:

- Spike a small bag (eg, 50 mL) of 0.9% Sodium Chloride, USP, with end of the Activase infusion set when the Activase vial is empty. The infusion should continue at the same rate

No medication should be added to infusion solutions that contain Activase.
For additional information regarding dosing and administration, please see the Activase full Prescribing Information.

Indication

Activase is indicated for the treatment of acute ischemic stroke. Exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment. Initiate treatment as soon as possible but within 3 hours after symptom onset.

Important Select Safety Information

Contraindications

Do not administer Activase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit: current intracranial hemorrhage (ICH); subarachnoid hemorrhage; active internal bleeding; recent (within 3 months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding; bleeding diathesis; and current severe uncontrolled hypertension.

Warnings and Precautions

Bleeding

Activase can cause significant, sometimes fatal, internal or external bleeding, especially at arterial and venous puncture sites. Avoid intramuscular injections and trauma to the patient. Fatal cases of hemorrhage associated with traumatic intubation in patients administered Activase have been reported. Heparin, aspirin, or Activase may cause bleeding complications; therefore carefully monitor for bleeding. If serious bleeding occurs, terminate the Activase infusion.

Orolingual Angioedema

Monitor patients during and for several hours after infusion for orolingual angioedema. If angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy.

Cholesterol Embolization

Cholesterol embolism, sometimes fatal, has been reported rarely in patients treated with thrombolytic agents.

Coagulation Tests May be Unreliable during Activase Therapy

Coagulation tests and/or measures of fibrinolytic activity may be unreliable during Activase therapy.

Adverse Reactions

The most frequent adverse reaction associated with Activase AIS therapy is bleeding.

Allergic-type reactions, e.g., anaphylactoid reaction, laryngeal edema, orolingual angioedema, rash, and urticaria have been reported.

Please see the accompanying full Prescribing Information for additional Important Safety Information.

Weight (lb)	Weight (kg)	Total Dose	Discard Quantity*	Bolus Dose (over 1 minute)	Infusion Dose (over 60 minutes)
90	40.9	36.8	63.2	3.7	33.1
92	41.8	37.6	62.4	3.8	33.8
94	42.7	38.4	61.6	3.8	34.6
96	43.6	39.2	60.8	3.9	35.3
98	44.5	40.1	59.9	4.0	36.1
100	45.5	41.0	59.0	4.1	36.9
102	46.4	41.8	58.2	4.2	37.6
104	47.3	42.6	57.4	4.3	38.3
106	48.2	43.4	56.6	4.3	39.1
108	49.1	44.2	55.8	4.4	39.8
110	50.0	45.0	55.0	4.5	40.5
112	50.9	45.8	54.2	4.6	41.2
114	51.8	46.6	53.4	4.7	41.9
116	52.7	47.4	52.6	4.7	42.7
118	53.6	48.2	51.8	4.8	43.4
120	54.6	49.1	50.9	4.9	44.2
122	55.5	50.0	50.0	5.0	45.0
124	56.4	50.8	49.2	5.1	45.7
126	57.3	51.6	48.4	5.2	46.4
128	58.2	52.4	47.6	5.2	47.2
130	59.1	53.2	46.8	5.3	47.9
132	60.0	54.0	46.0	5.4	48.6
134	60.9	54.8	45.2	5.5	49.3
136	61.8	55.6	44.4	5.6	50.0
138	62.7	56.4	43.6	5.6	50.8
140	63.6	57.2	42.8	5.7	51.5
142	64.5	58.1	41.9	5.8	52.3
144	65.5	59.0	41.0	5.9	53.1
146	66.4	59.8	40.2	6.0	53.8
148	67.3	60.6	39.4	6.1	54.5
150	68.2	61.4	38.6	6.1	55.3
152	69.1	62.2	37.8	6.2	56.0
154	70.0	63.0	37.0	6.3	56.7
156	70.9	63.8	36.2	6.4	57.4
158	71.8	64.6	35.4	6.5	58.1
160	72.7	65.4	34.6	6.5	58.9
162	73.6	66.2	33.8	6.6	59.6
164	74.5	67.1	32.9	6.7	60.4
166	75.5	68.0	32.0	6.8	61.2
168	76.4	68.8	31.2	6.9	61.9
170	77.3	69.6	30.4	7.0	62.6
172	78.2	70.4	29.6	7.0	63.4
174	79.1	71.2	28.8	7.1	64.1
176	80.0	72.0	28.0	7.2	64.8
178	80.9	72.8	27.2	7.3	65.5
180	81.8	73.6	26.4	7.4	66.2
182	82.7	74.4	25.6	7.4	67.0
184	83.6	75.2	24.8	7.5	67.7
186	84.5	76.1	23.9	7.6	68.5
188	85.5	77.0	23.0	7.7	69.3
190	86.4	77.8	22.2	7.8	70.0
192	87.3	78.6	21.4	7.9	70.7
194	88.2	79.4	20.6	7.9	71.5
196	89.1	80.2	19.8	8.0	72.2
198	90.0	81.0	19.0	8.1	72.9
200	90.9	81.8	18.2	8.2	73.6
202	91.8	82.6	17.4	8.3	74.3
204	92.7	83.4	16.6	8.3	75.1
206	93.6	84.2	15.8	8.4	75.8
208	94.5	85.1	14.9	8.5	76.6
210	95.5	86.0	14.0	8.6	77.4
212	96.4	86.8	13.2	8.7	78.1
214	97.3	87.6	12.4	8.8	78.8
216	98.2	88.4	11.6	8.8	79.6
218	99.1	89.2	10.8	8.9	80.3
≥220	≥100.0	90.0	10.0	9.0	81.0

*Calculations based on 100-mg vial of Activase.

ACTIVASE® ALTEPLASE
A RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR

www.activase.com

Reference: 1. Activase [prescribing information]. South San Francisco, CA: Genentech, Inc; 2017.

Genentech
A Member of the Roche Group

Printed in USA. ACI/121614/0041(2)